Searchable abstracts of presentations at key conferences in endocrinology

ea0085nep2.1 | Endocrine Symposium 4 | BSPED2022

Immune dysregulation driving future risk of disease in children with obesity

DeBarra Conor , Tobin Laura , O'Shea Donal , Cody Declan , Hogan Andrew

Obesity is linked to an increased risk of 13 different cancers in adulthood. The environment supporting this increased risk is multi-factorial but includes metabolic dysregulation, chronic inflammation and the loss of the anti-tumour activity of cells such natural killer (NK) cells. We present data which shows that this pro-cancer environment starts early in children with obesity, potentially increasing their risk of future disease. We investigated a cohort of 50 children with...

ea0095p142 | Obesity 2 | BSPED2023

Immune modulatory response to rituximab in ROHHAD syndrome

Hawton Katherine , Hogan Andrew , Hamilton-Shield Julian , Giri Dinesh

Background: Rapid-onset obesity with hypoventilation, hypothalamic dysfunction, autonomic dysregulation (ROHHAD) is a rare syndrome associated with high morbidity. An immune-inflammatory aetiology has been postulated; however, the immune characteristics and effect of immunomodulation have not been well described.Case report: We describe the immune profile and the effect of rituximab on the immunomodulation potentially ca...

ea0049ep696 | Obesity | ECE2017

GLP-1 therapy and the immune system – can we predict responders from non-responders?

O'Shea Donal , Tobin Laura , Cody Declan , Mat Arimin , Kinlen David , Hogan Andrew

Abstract: Obesity has reached epidemic proportions globally. At least 2.8 million people die each year as a result of being overweight or obese, the biggest burden being obesity-related diseases. Glucagon like peptide 1 (GLP-1) targeted therapies show the greatest potential for intervention and are approved as weight loss agents. However not all patients respond to GLP-1 therapy. Understanding the mechanisms of bodyweight regulation and their role in GLP-1 responders vs. non-r...

ea0035p499 | Diabetes therapy | ECE2014

Differential effects of native Peptide YY and its long acting analogue (Y-59) on innate lymphocyte function and anti-tumour activity

Hogan Andrew , Tobin Laura , Corrigan Michelle , Gilshinan Colm , Ghatei Mohammad , Bloom Stephen , O'Shea Donal

Background: Peptide-YY is synthesised and secreted by specialised cells in the ileum and colon. Levels increase following food intake, having a satiety effect. Baseline and postprandial levels of PYY were found to be lower in obese subjects compared to lean, negatively correlating with the subjects BMI, however obese subjects were sensitive to the anorectic effects of PYY when given exogenous PYY.Hypothesis: We have recently demonstrated that another pra...

ea0035p791 | Obesity | ECE2014

Childhood obesity alters innate T cell frequency and function resulting in loss of regulation and increased inflammation

Hogan Andrew , Carolan Eirin , Mangan Bozgana , Corrigan Michelle , Doherty Derek , Cody Declan , O'Shea Donal

Background: Childhood obesity now represents a major public health concern. Being obese in childhood appears to increase the risk of severe obesity in adulthood. Obesity is associated with co-morbid conditions such as type 2 diabetes and cardiovascular disease. Underpinning obesity is a state of chronic sterile inflammation. Recently the invariant natural killer T (iNKT) cell, an innate T cell was shown to act as a metabolic regulator and altered by obesity both in adults and ...

ea0033oc3.5 | Oral Communications 3 | BSPED2013

Loss of the tumour suppressor micro-RNA 34a, and anti tumour cellular immunity in paediatric obesity – is obesity increasing the future risk of cancer in children?

Carolan Eirin , Hogan Andrew , Corrigan Michelle , O'Connell Jean , Foley Niamh , O'Neill Luke , Cody Declan , O'Shea Donal

There is strong epidemiological data linking obesity to an increased risk of various cancers. It is associated with immune dysregulation and chronic low grade inflammation, however little is known about its impact on anti-tumour immunity. Whether childhood obesity is an independent risk factor for future malignancy is not fully established. We hypothesized that alterations in key immune anti-tumour mechanisms begin prior to adulthood in paediatric obesity.<p class="abstext...

ea0033p64 | (1) | BSPED2013

Immune cell dysregulation – contributing to the risk of development of metabolic disease in childhood obesity

Carolan Eirin , Hogan Andrew , Corrigan Michelle , O'Connell Jean , Foley Niamh , O'Neill Luke , Cody Declan , O'Shea Donal

Background: Although the association between obesity, chronic low-grade inflammation and immune dysregulation is well described in adults, there is a paucity of literature regarding this in children. We hypothesized that childhood obesity is associated with significant immune dysregulation.Methods: Expression of cytokines and microRNAs (miR) involved in the pathogenesis of metabolic disease were assessed in 49 participants aged 6–18 years. Invariant...